Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Table 3

Anatomical outcomes for 72 months in eyes with PCV by optical coherence tomography.

	Subtype 1		Subtype 2
	Anti-VEGF monotherapy	Combination therapy	Anti-VEGF monotherapy	Combination therapy
Intraretinal fluid	5	6	3	1
Subretinal fluid	1	4	6	0
Macular atrophy	0	5	3	4

PCV, polypoidal choroidal vasculopathy; VEGF, vascular endothelial growth factor.